Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company demonstrated strong resilience in performance during the off-season, with Q3 2024 revenue increasing by 20.1% year-on-year and net profit attributable to shareholders rising by 32% [2][6] - The company plans to invest 700 million yuan in the construction of the "Runben Intelligent Manufacturing Future Factory Project," which aims to enhance product innovation capabilities and increase production capacity [6] - The "Big Brand + Small Category" strategy continues, with projected revenues for 2024-2026 expected to be 1.332 billion, 1.701 billion, and 2.101 billion yuan, respectively, reflecting growth rates of 29.0%, 27.6%, and 23.5% [6] Financial Performance Summary - For the first three quarters of 2024, the company reported revenue of 1.038 billion yuan (up 26.0% year-on-year) and a net profit of 261 million yuan (up 44.3% year-on-year) [6] - Q3 2024 financial metrics include a gross margin of 57.6% (up 0.11 percentage points year-on-year), a sales expense ratio of 23.5% (up 1.45 percentage points), and a net profit margin of 27.55% (up 2.48 percentage points) [2][6] - The company’s earnings per share (EPS) for 2024-2026 are projected to be 0.79, 1.00, and 1.20 yuan per share, with corresponding price-to-earnings (P/E) ratios of 33.5x, 26.5x, and 22x [6]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company reported a revenue of 1.04 billion yuan for the first three quarters of 2024, representing a year-over-year increase of 26.0%. The net profit attributable to the parent company was 260 million yuan, up 44.4% year-over-year [2] - The company is successfully cultivating new products, with the baby care segment maintaining high growth. In Q3 2024, revenue from baby care, mosquito repellent, and essential oil products increased by 27%, 16%, and 15% year-over-year, respectively [2] - The gross margin continues to trend upwards, with a gross margin of 58.3% for the first three quarters of 2024, an increase of 2.2 percentage points year-over-year [2] Financial Performance Summary - Total revenue (in million yuan) is projected to grow from 1,032.96 in 2023 to 1,339.92 in 2024, reflecting a year-over-year growth of 29.72% [1] - The net profit attributable to the parent company is expected to rise from 226.03 million yuan in 2023 to 312.69 million yuan in 2024, indicating a year-over-year increase of 38.34% [1] - The latest diluted EPS is forecasted to increase from 0.56 yuan in 2023 to 0.77 yuan in 2024 [1] Cash Flow and Valuation Metrics - Operating cash flow for 2024 is projected to be 302 million yuan, up from 253 million yuan in 2023 [9] - The company’s P/E ratio is expected to decrease from 47.40 in 2023 to 34.26 in 2024, indicating an improving valuation [9] - The return on equity (ROE) is projected to increase from 11.76% in 2023 to 14.47% in 2024 [9]

重要内容提示： 证券代码： 603193 证券简称：润本股份 公告编号：2024-042 润本生物技术股份有限公司 关于使用部分超募资金永久补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1 ● 公司承诺：用于永久补充流动资金的金额，每十二个月内累计不超募资金 总额的30%；在补充流动资金后的十二个月内不得进行高风险投资及为控股子 公司以外的对象提供财务资助。 ● 履行的审议程序：本事项已分别经第二届董事会第六次会议和第二届监事 会第四次会议审议通过；保荐人申万宏源证券承销保荐有限责任公司（以下简称 "保荐人"）发表了无异议的核查意见。 ●该事项尚需提交公司2024年第三次临时股东大会审议。 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意润本生物技术股份有限公司 首次公开发行股票注册的批复》（证监许可[2023]1631号），公司于2023年9 月27 日首次公开发行人民币普通股（A股）60,690,000股，发行价格为人民币 17.38元/股，募集资金总额为人民币1,054,792,200 ...

证券代码：603193 证券简称：润本股份 公告编号： 2024-039 润本生物技术股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 重要内容提示： ● 润本生物技术股份有限公司拟续聘广东司农会计师事务所（特殊普通合伙） 作为公司 2024 年度的财务审计机构和内控审计机构。 润本生物技术股份有限公司（以下简称"公司"）于2024 年 10 月 22 日召开 第二届董事会第六次会议和第二届监事会第四次会议，审议通过了《关于续聘会计 师事务所的议案》，同意续聘请广东司农会计师事务所（特殊普通合伙）（以下简称 "司农会计师事务所"）为公司2024 年度财务报告及内部控制审计机构，该事项尚需 提交公司股东大会审议通过，现将有关情况公告如下： 一、拟聘任会计师事务所的基本情况 （一）机构信息 1. 基本信息 会计师事务所名称：广东司农会计师事务所（特殊普通合伙） 成立日期：2020 年 11 月 25 日 组织形式：合伙企业（特殊普通合伙） 注册地址：广州市南沙区南沙街兴沙路 6 号 704 房- ...

一、监事会会议召开情况 润本生物技术股份有限公司 第二届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 润本生物技术股份有限公司（以下简称"公司"）第二届监事会第四次会议 于 2024 年 10 月 22 日在公司会议室以现场方式召开。会议通知已于2024 年 10 月 17 日通过书面文件的方式送达各位监事。本次会议应出席监事 3 人，实际出席 监事 3 人，会议由监事会主席秦传晓先生主持。董事会秘书吴伟斌先生列席了本 次会议。本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。经各位监事认真审议，会议形成了如下决议。 二、监事会会议审议情况 （一）审议通过《关于<2024 年第三季度报告>的议案》 证券代码：603193 证券简称：润本股份 公告编号：2024-036 2024 年前三季度公司实现营业收入 10.38 亿元，同比增长 25.98%，实现归 属于母公司净利润 2.61 亿元，同比增长 44.35%。公司监事会认为公司《2024 年第三季度 ...

证券代码：603193 证券简称：润本股份 公告编号：2024-040 润本生物技术股份有限公司 关于召开 2024 年第三次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024 年第三次临时股东大会 召开的日期时间：2024 年 11 月 11 日 14 点 00 分 召开地点：广东省广州市天河区华夏路 28 号富力盈信大厦 40 楼润本生物 技术股份有限公司会议室 股东大会召开日期：2024年11月11日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 11 月 11 日 至 2024 年 11 月 11 日 采用上海证券交易所 ...

润本生物技术股份有限公司 章 程 二〇二三 年十二月 | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 2 | | 第三章 股 | 份 | 2 | | 第一节 | 股份发行 | 2 | | 第二节 | 股份增减和回购 | 3 | | 第三节 | 股份转让 | 4 | | 第四章 | 股东和股东大会 | 6 | | 第一节 | 股东 | 6 | | 第二节 | 股东大会的一般规定 | 9 | | 第三节 | 股东大会的召集 | 12 | | 第四节 | 股东大会的提案与通知 | 14 | | 第五节 | 股东大会的召开 | 16 | | 第六节 | 股东大会的表决和决议 | 19 | | 第五章 | 董事会 | 25 | | 第一节 | 董事 | 25 | | 第二节 | 董事会 | 32 | | 第六章 | 总经理及其他高级管理人员 | 47 | | 第七章 | 监事会 | 50 | | 第一节 | 监事 | 50 | | 第二节 | 监事会 | 51 | | 第八章 | 财务会计制度、利润分配和审计 | 52 | | 第一节 | 财务会计制度 | ...

证券代码：603193 证券简称：润本股份 公告编号：2024-035 润本生物技术股份有限公司 该议案已经第二届董事会审计委员会第三次会议审议通过。 表决结果：5票同意，0 票反对，0 票弃权。 第二届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 润本生物技术股份有限公司（以下简称"公司"）第二届董事会第六次会议 于 2024 年 10 月 22 日在公司会议室以现场的方式召开。会议通知已于 2024 年 10 月 17 日通过书面文件、电子邮件的方式送达各位董事。本次会议应出席董事 5 人，实际出席董事 5 人。董事长赵贵钦先生为会议主持人，公司监事及高级管理 人员列席会议。本次会议的召集、召开和表决程序符合《公司法》等有关法律、 行政法规、部门规章、规范性文件和《公司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，会议形成了如下决议： （一）审议通过《关于<2024 年第三季度报告>的议案》 2024 年前三季度公司实现营业收入 10.38 亿元，同比增长 ...

Revenue and Profit - Revenue for Q3 2024 reached ¥293,487,968.39, an increase of 20.10% year-over-year, while year-to-date revenue totaled ¥1,037,514,293.85, up 25.98% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥80,857,081.05, reflecting a 31.98% increase year-over-year, with a year-to-date net profit of ¥260,884,103.81, up 44.35%[2] - The net profit excluding non-recurring gains and losses for Q3 2024 was ¥80,356,454.74, a 37.16% increase year-over-year, while the year-to-date figure was ¥255,806,810.05, up 44.45%[2] - Total operating revenue for the first three quarters of 2024 reached CNY 1,037,514,293.85, a 26% increase compared to CNY 823,525,155.95 in the same period of 2023[13] - Net profit for the first three quarters of 2024 was CNY 260,884,103.81, compared to CNY 180,733,960.84 in 2023, representing a 44% increase[14] - The total comprehensive income for the first three quarters of 2024 was CNY 260,884,103.81, up from CNY 180,733,960.84 in 2023[15] Earnings Per Share - Basic and diluted earnings per share for Q3 2024 were both ¥0.20, representing an 11.11% increase year-over-year, while year-to-date earnings per share were ¥0.64, up 20.75%[3] - Basic and diluted earnings per share for the first three quarters of 2024 were both CNY 0.64, up from CNY 0.53 in the same period of 2023[15] Cash Flow - Operating cash flow for Q3 2024 was ¥38,762,310.73, a decrease of 37.65% compared to the same period last year, primarily due to increased cash payments for goods and services[7] - The net cash flow from operating activities for Q3 2024 was ¥179,625,103.80, a decrease from ¥190,109,983.91 in Q3 2023[17] - The total cash outflow from operating activities amounted to ¥984,505,277.75, compared to ¥742,108,253.09 in the same period last year, indicating a significant increase[17] - Cash inflow from operating activities for the first three quarters of 2024 was CNY 1,164,130,381.55, compared to CNY 932,218,237.00 in 2023, indicating a 25% increase[16] Assets and Liabilities - Total assets as of the end of Q3 2024 were ¥2,218,431,867.35, a 9.88% increase from the end of the previous year[3] - Current assets totaled RMB 1,857,746,872.92, up from RMB 1,716,333,346.68, indicating an increase of about 8.20%[11] - Total liabilities amounted to RMB 177,319,929.31, compared to RMB 97,612,508.38, reflecting a significant increase of about 81.67%[12] - Shareholders' equity attributable to the parent company was ¥2,041,111,938.04, reflecting a 6.24% increase from the end of the previous year[3] - Shareholders' equity reached RMB 2,041,111,938.04, up from RMB 1,921,258,411.52, indicating a growth of approximately 6.25%[12] Cash and Investments - Cash and cash equivalents decreased to RMB 129,406,720.91 from RMB 243,825,181.77, representing a decline of approximately 47%[10] - The company reported a significant increase in investment income, reaching CNY 1,032,962.19 in 2024 compared to CNY 499,646.25 in 2023[14] - Cash inflow from investment activities reached ¥652,519,848.79, up from ¥130,349,646.25 in Q3 2023[17] - The net cash flow from investment activities was -¥259,172,089.84, worsening from -¥95,787,407.44 year-over-year[17] Expenses - Total operating costs for the first three quarters of 2024 were CNY 741,942,471.37, up from CNY 611,989,929.02 in 2023, reflecting a 21% increase[13] - Research and development expenses for the first three quarters of 2024 amounted to CNY 24,613,948.05, an increase from CNY 18,255,343.87 in 2023[13] - Sales expenses for the first three quarters of 2024 were CNY 282,898,111.64, compared to CNY 208,669,343.31 in 2023, marking a 36% increase[13] Shareholder Information - The total number of common shareholders at the end of the reporting period was 13,229, with the largest shareholder holding 44.58% of the shares[8] - There were no changes in the top 10 shareholders or their participation in financing activities during the reporting period[10] Other Information - The company received government subsidies amounting to ¥173,173.09 in Q3 2024, contributing to the overall profit[4] - The company has not disclosed any new product developments or market expansion strategies in this report[10] - The company did not apply new accounting standards for the current fiscal year[18]

申万宏源证券承销保荐有限责任公司 关于润本生物技术股份有限公司 使用部分超募资金永久补充流动资金 的核查意见 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源"或"保荐人"） 作为润本生物技术股份有限公司（以下简称"润本股份"或"公司"）首次公开 发行股票并在主板上市持续督导保荐人，根据《上市公司监管指引第 2 号——上 市公司募集资金管理和使用的监管要求》《上海证券交易所股票上市规则》《上海 证券交易所上市公司自律监管指引第 11 号——持续督导》《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》等相关规定，对公司使用部分超募资金 永久补充流动资金的事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意润本生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可[2023]1631 号），公司于 2023 年 9 月 27 日首次公开发行人民币普通股（A 股）60,690,000 股，发行价格为人民币 17.38 元/股，募集资金总额为人民币 1,054,792,200.00 元，扣除不含税的发行费用人民 币 83,563,748.31 元，实际募 ...